Date: 2014-11-03
Type of information: Collaboration agreement
Compound: Tumor BRACAnalysis CDx™
Company: Myriad Genetics (USA - UT) AbbVie (USA - IL)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism: Tumor BRACAnalysis CDx is a companion diagnostic test for identifying both germline and somatic cancer-causing mutations in the BRCA1 and BRCA2 genes. Tumor BRACAnalysis CDx has undergone significant analytic validation and has been shown to identify up to 50 percent more patients with cancer-causing BRCA 1/2 mutations compared to germline testing alone. Myriad is actively collaborating with leading pharmaceutical companies to use Tumor BRACAnalysis CDx as a companion diagnostic with certain PARP inhibitors, platinum-based drugs and other chemotherapeutic agents. In the United States, the testing will be done at the Company\'s laboratory in Salt Lake City. In Europe, the CE-marked test will be performed at the Company\'s Munich laboratory.
Disease:
Details: * On November 3, 2014, Myriad Genetics announced that it has signed an expanded companion diagnostic agreement with AbbVie to use Tumor BRACAnalysis CDx™ as a companion diagnostic in support of AbbVie\'s novel poly (ADP-ribose) polymerase or PARP inhibitor, veliparib. The collaboration builds upon Myriad\'s previous agreements with AbbVie under which the company is providing BRACAnalysis CDx testing to support several of AbbVie\'s ongoing Phase 3 clinical studies of veliparib, including neo-adjuvant and metastatic breast cancer.
Financial terms:
Latest news:
